Vadadustat (Vafseo) Dosing and Monitoring for Dialysis-Dependent CKD
Start vadadustat at 300 mg orally once daily for all adult patients with dialysis-dependent CKD who have been on dialysis for at least 3 months, regardless of whether they are ESA-naïve or switching from an ESA. 1
Pre-Treatment Requirements
Before initiating vadadustat, you must:
- Exclude other causes of anemia (vitamin deficiency, chronic inflammation, bleeding) 1
- Measure baseline hemoglobin 1
- Assess iron status: Check serum ferritin and transferrin saturation 1
- Supplement iron when ferritin <100 mcg/L or TSAT <20%
- Most CKD patients will require supplemental iron during treatment
- Obtain baseline liver function tests: ALT, AST, and bilirubin 1
Starting Dose
300 mg once daily for all patients 1
- Take with or without food
- Swallow whole (do not cut, crush, or chew)
- Can be given regardless of dialysis timing or type
- Administer at least 1 hour before oral iron or iron-containing phosphate binders 1
- Give at least 1 hour before or 2 hours after non-iron-containing phosphate binders 1
Special Considerations When Switching from ESA
When converting from ESA to vadadustat, still start at 300 mg daily 1. During the transition:
- Consider RBC transfusion or temporary ESA rescue if Hb falls below 9 g/dL
- If ESA rescue is needed, pause vadadustat and resume when Hb ≥10 g/dL
- After ESA rescue, wait before resuming vadadustat:
- 2 days after last epoetin dose
- 7 days after last darbepoetin alfa dose
- 14 days after last methoxy polyethylene glycol-epoetin beta dose
- Resume at prior dose or 150 mg higher than prior dose 1
Monitoring Protocol
Hemoglobin Monitoring
Monitor Hb every 2 weeks after initiation and after each dose adjustment until stable, then at least monthly. 1
Target Hb range: 10-11 g/dL 1
- Never target Hb >11 g/dL due to increased risk of death, MI, stroke, and thrombosis 1
Liver Function Monitoring
Measure ALT, AST, and bilirubin monthly for the first 6 months, then as clinically indicated. 1
Discontinue vadadustat if:
- Persistent ALT or AST >3× ULN, OR
- ALT or AST >3× ULN with bilirubin >2× ULN 1
Dose Titration Algorithm
Adjust dose in 150 mg increments (range: 150-600 mg maximum) 1
When to Increase Dose
- Increase no more frequently than every 4 weeks if Hb remains below target 1
When to Decrease or Hold Dose
- If Hb rises >1 g/dL in any 2-week period OR >2 g/dL in 4 weeks: Interrupt or reduce dose 1
- If Hb exceeds 11 g/dL: Hold vadadustat until Hb ≤11 g/dL, then resume at 150 mg less than prior dose 1
- Decreases can occur more frequently than increases 1
When to Discontinue
Stop vadadustat after 24 weeks if no clinically meaningful Hb increase is achieved. Investigate alternative causes of inadequate response before restarting. 1
Critical Safety Warnings
Cardiovascular Risk (Black Box Warning)
Vadadustat increases risk of death, MI, stroke, venous thromboembolism, and vascular access thrombosis 1. In the INNO2VATE trials, vadadustat showed a hazard ratio of 1.17 (95% CI 1.01-1.36) for first MACE compared to darbepoetin alfa in pooled analysis 2.
Avoid in patients with:
- MI, stroke, or acute coronary syndrome within 3 months prior to starting 1
- Uncontrolled hypertension (absolute contraindication) 1
Counsel patients to seek immediate care for symptoms of MI, stroke, VTE, or access thrombosis. 1
Hepatotoxicity
Hepatocellular injury occurred in <1% of patients in trials, typically within first 3 months 1. All cases resolved after discontinuation.
Clinical Trial Context
The INNO2VATE trials demonstrated that vadadustat achieved Hb target range (10-11 g/dL in US, 10-12 g/dL non-US) in approximately 44-50% of dialysis patients at weeks 40-52, with mean Hb changes of 0.23-0.43 g/dL 2. However, vadadustat showed slightly lower Hb levels compared to darbepoetin alfa (LSMD -0.17 to -0.18 g/dL) 2.
Real-world Japanese surveillance data showed mean Hb increases of 0.18-0.30 g/dL in ESA-switched patients and 0.34-0.90 g/dL in ESA-naïve patients over 12 months 3.
Common Pitfalls to Avoid
- Do not target Hb >11 g/dL – this substantially increases cardiovascular risk 1
- Do not increase dose more frequently than every 4 weeks – allow time for erythropoietic response 1
- Do not co-administer with oral iron or phosphate binders without proper timing separation 1
- Do not continue beyond 24 weeks without response – investigate hyporesponsiveness 1
- Do not forget monthly liver monitoring for first 6 months – hepatotoxicity typically occurs early 1